Detalhe da pesquisa
1.
Safety and Immunogenicity of Respiratory Syncytial Virus Pre-fusion Maternal Vaccine Co-administered with Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study.
J Infect Dis
; 2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38133639
2.
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
Clin Infect Dis
; 74(8): 1459-1467, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34283213
3.
Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study.
Respir Res
; 23(1): 114, 2022 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35509077
4.
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.
J Infect Dis
; 219(11): 1799-1803, 2019 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30715452
5.
Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
J Infect Dis
; 214(11): 1717-1727, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27609809
6.
Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults.
Vaccine X
; 18: 100494, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38746060
7.
Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.
J Infect Dis
; 205(5): 733-44, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22315336
8.
A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study.
Vaccine
; 39(45): 6628-6636, 2021 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34635373
9.
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine.
Vaccine
; 37(9): 1209-1218, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30691980
10.
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50â¯years of age: A randomized trial.
Vaccine
; 36(29): 4278-4286, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29903674
11.
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial.
Vaccine
; 35(15): 1865-1872, 2017 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28302407
12.
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
Vaccine
; 35(10): 1431-1439, 2017 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28187952
13.
Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus.
Hum Vaccin Immunother
; 12(8): 2197-2203, 2016 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27123743
14.
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Lancet Infect Dis
; 16(10): 1154-1168, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27373900
15.
Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants.
Vaccine
; 33(16): 1897-900, 2015 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25701314
16.
Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50â¯years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286].
Vaccine
; 37(9): 1252-1253, 2019 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30711316
17.
Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.
Hum Vaccin Immunother
; 10(5): 1155-65, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24576907